Formation of an association between factor XII and kallikrein in human plasma--significance of storage of plasma and the functional state of plasma kallikrein.
In a previous study evidence was provided that zymogen FXII might associate with part of the kallikrein generated by acetone treatment of human plasma in the presence of benzamidine (Thromb. Res. 61, 123-133, 1991). Some results also suggested an increase in such a complex formation upon storage of plasma, and two questions were raised in the present study: Does kallikrein activated by acetone-treatment of plasma exist in modifications with different abilities to associate with FXII? And will -70 degrees storage of plasma increase the liability to complex formation? S-2302 amidase assays carried out in mixtures of normal plasma and plasma genetically deficient in prekallikrein (PK) suggested an inhomogeneity of the kallikrein generated. A minor and unstable part of it could be blocked by corn trypsin inhibitor, thus indicating the presence of an association with FXII. In fractions from gel filtration of acetone-activated plasma, kallikrein was assayed as S-2302 amidase, high molecular weight kininogen (HK) was measured in rocket immunoassay, and FXII, PK and HK were studied in PAGE immunoblot experiments. When freshly collected plasma was used, an amidase double peak (mol. wts. 400 and 300 kD) indicated an inhomogeneity of the kallikrein present, HK being observed in both peaks. FXII eluted separately over a gel. mol. wt. range of 90-55 kD. When plasma was stored at -70 degrees for 10 months before use, the more low-molecular part of the kallikrein double-peak had disappeared and was recovered, in a highly unstable state, adsorbed to the column material together with HK and FXII. Accordingly both functional assays and the results of immunoblot experiments indicated an inhomogeneity of the kallikrein present, and also a tendency of the minor part of it to associate with FXII, a tendency increased upon storage of plasma at -70 degrees.
Hoem
N O
NO
Department of Pharmacology, University of Oslo, Norway.
Johannesen
S
S
Briseid
K
K
D000096:Acetone / Q000494:pharmacology; D001550:Benzamidines / Q000494:pharmacology; D001769:Blood / Q000187:drug effects; D001793:Blood Preservation; D002850:Chromatography, Gel; D002863:Chromogenic Compounds; D004789:Enzyme Activation / Q000187:drug effects; D005174:Factor XII / Q000378:metabolism*; D005175:Factor XII Deficiency / Q000097:blood; D006801:Humans; D015151:Immunoblotting; D007610:Kallikreins / Q000378:metabolism*; D007704:Kininogens / Q000032:analysis; D009842:Oligopeptides; D011288:Prekallikrein / Q000172:deficiency
D001550:Benzamidines; D002863:Chromogenic Compounds; D007704:Kininogens; D009842:Oligopeptides; D000096:Acetone; C026148:prolyl-phenylalanyl-arginine-4-nitroanilide; D005174:Factor XII; D011288:Prekallikrein; D007610:Kallikreins; C032157:benzamidine